Subscribe To

Price Alert Latest News Economic Calendar News

NNVC / NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says. Read More

Demo Live Account See Partner Details

Content Topics

Nanoviricides

Starts

Drug

Development

Program

Recent

Cases

Unexplained

Pediatric

Hepatitis

Stock

NNVC

Posted: May 16 2022, 12:26

Author Name: Benzinga

NNVC News

By Proactive Investors
October 16, 2023

NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus

NanoViricides (NYSE-A:NNVC) said it has sufficient funds to complete its ongoing Phase 1a/1b clinical trial of its lead drug candidate NV-CoV-2 based

By Accesswire
October 12, 2023

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. An

By Proactive Investors
August 21, 2023

NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug

NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing succes

By Proactive Investors
July 13, 2023

NanoViricides creating special purpose nanomaterials for antiviral therapy

As a war often accelerates technological innovation, the recent coronavirus pandemic in 2020 provided a big spur to advancements in biotechnology, wit

By Proactive Investors
July 11, 2023

NanoViricides reveals promising efficacy of its antiviral drug candidate in combating RSV

NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate NV-387 in combating Respiratory Syncytial Virus

By Proactive Investors
July 6, 2023

NanoViricides says clinical trial progressing satisfactorily for its broad-spectrum antiviral drug

NanoViricides Inc (NYSE-A:NNVC) has announced that the clinical trial of its broad-spectrum antiviral drug, NV-CoV-2, is progressing satisfactorily. T

By Proactive Investors
June 29, 2023

NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2

NanoViricides Inc (NYSE-A:NNVC) has announced that clinical trials for its broad-spectrum antiviral drug NV-CoV-2 commenced on June 17, 2023. The tri

By Accesswire
May 31, 2023

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.